Titan Biotech FY26 Results: Profit ₹27.45 Crore, Dividend ₹0.50 Recommended

Standalone Profit for the Year Ended March 31, 2026: ₹27.45 crore
Consolidated Total Comprehensive Income for the Year Ended March 31, 2026: ₹29.80 crore

Reader Takeaway: Solid annual profit and dividend payout announced; watch for dividend record date details.

What just happened

Titan Biotech Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The company reported standalone revenue from operations of ₹206.19 crore. Its standalone profit for the period was ₹27.45 crore, and consolidated Total Comprehensive Income stood at ₹29.80 crore.

The Board of Directors has recommended a dividend of ₹0.50 per equity share for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM).

Why this matters

These results confirm the company's financial performance for the fiscal year. The dividend recommendation offers a direct return to shareholders. An unmodified opinion from the statutory auditors indicates that the company's financial statements are reliable.

The backstory

Titan Biotech completed a share subdivision effective February 20, 2026, where its ₹10 face value equity shares were split into ₹2 face value shares in a 1:5 ratio. This increased the total number of shares from 82,63,700 to 4,13,18,500.
The company has also opted to exercise its right under section 115BAA of the Income Tax Act, 1961.

What changes now

Shareholders will be eligible for the recommended dividend once approved by the AGM and if their name appears on the company's register by the yet-to-be-announced record date. The share subdivision has already altered the number of shares outstanding.

Risks to watch

No specific risks were detailed in the filing. However, dividend payout is subject to shareholder approval and company performance. Fluctuations in raw material costs or regulatory changes could impact future profitability.

Peer comparison

While specific peer data is not provided in the filing, Titan Biotech operates in the biotechnology sector, which is generally characterized by R&D intensity and market competition.

Context metrics (time-bound)

• Revenue from operations (Standalone): ₹206.19 crore for the year ended March 31, 2026.
• Profit for the period (Standalone): ₹27.45 crore for the year ended March 31, 2026.
• Consolidated Total Comprehensive Income: ₹29.80 crore for the year ended March 31, 2026.
• Dividend recommended: ₹0.50 per equity share.
• CSR Expenditure: ₹0.565 crore for the year ended March 31, 2026.

What to track next

Investors should look out for the announcement of the dividend record date and payment details. Monitoring future financial results and any updates on the company's business expansion or new product developments will also be important.